Show simple item record

dc.contributor.authorOsuji, Nen_US
dc.contributor.authorDel Giudice, Ien_US
dc.contributor.authorMatutes, Een_US
dc.contributor.authorMorilla, Aen_US
dc.contributor.authorOwusu-Ankomah, Ken_US
dc.contributor.authorMorilla, Ren_US
dc.contributor.authorDunlop, Aen_US
dc.contributor.authorCatovksy, Den_US
dc.date.accessioned2018-09-07T09:01:38Z
dc.date.issued2005-05en_US
dc.identifier5en_US
dc.identifier.citationLEUKEMIA & LYMPHOMA, 2005, 46 pp. 723 - 727en_US
dc.identifier.issn1042-8194en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2577
dc.identifier.doi10.1080/10428190500052156en_US
dc.description.abstractFew reports on the successful treatment of T-cell large granular lymphocyte (LGL) leukemia with the humanized anti-CD52 monoclonal antibody alemtuzumab are emerging in the literature. The expression of CD52 by LGLs has not been previously investigated. Using semi-quantitative 2- and 3-color flow cytometry, we documented the expression of CD52 in 100% of abnormal cells in T-cell LGL leukemia (n = 11) and natural killer (NK) cell LGL leukemia (n = 2), and showed no significant difference in CD52 expression between T-cell prolymphocytic leukemia (PLL) and T-cell LGL leukemia. Higher CD52 expression has been noted in responders to alemtuzumab in T-cell PLL and in chronic lymphocytic leukemia (CLL), a B-cell disorder. The strong and consistent expression of CD52 shown here highlights the potential role of alemtuzumab in the treatment of refractory T-cell LGL leukemia and possibly aggressive NK cell leukemia.en_US
dc.format.extent723 - 727en_US
dc.languageEnglishen_US
dc.language.isoEnglishen_US
dc.publisherTAYLOR & FRANCIS LTDen_US
dc.titleCD52 expression in T-cell large granular lymphocyte leukemia - Implications for treatment with alemtuzumaben_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1080/10428190500052156en_US
rioxxterms.licenseref.startdate2005-05en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfLEUKEMIA & LYMPHOMAen_US
pubs.notesaffiliation: Catovksy, D (Reprint Author), Royal Marsden NHS Trust, Sect Haematooncol, Fulham Rd, London SW3 6JJ, England. Royal Marsden NHS Trust, Sect Haematooncol, London SW3 6JJ, England. Inst Canc Res, London SW3 6JJ, England. keywords: LGL leukemia; T cell; alemtuzumab; flow cytometry; CD52 keywords-plus: LYMPHOPROLIFERATIVE DISORDERS; CAMPATH-1H; CYCLOSPORINE; THERAPY; ANTIGEN; LYSIS research-areas: Oncology; Hematology web-of-science-categories: Oncology; Hematology author-email: [email protected] researcherid-numbers: Del Giudice, Ilaria/K-6027-2016 orcid-numbers: Del Giudice, Ilaria/0000-0001-6864-9533 number-of-cited-references: 17 times-cited: 26 usage-count-last-180-days: 0 usage-count-since-2013: 1 journal-iso: Leuk. Lymphoma doc-delivery-number: 933IE unique-id: ISI:000229621300010 da: 2018-09-06en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.volume46en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMolecular Haematology (including Cytogenetics Group and Cell Markers)en_US
dc.contributor.icrauthorCatovsky, Danielen_US
dc.contributor.icrauthorMatutes, Estellaen_US
dc.contributor.icrauthorMorilla, Alisonen_US
dc.contributor.icrauthorOsuji, NNennaen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record